Eukaryotic messenger RNAs are synthesized by the multisubunit enzyme RNA polymerase II, aided by myriad cofactors that control different events in this multistep process. A complete round of transcription involves: the recruitment of polymerase and general transcription factors to the promoter, RNA chain initiation and polymerase escape from the promoter, RNA chain elongation, and finally termination with release of polymerase and nascent transcript from the DNA template [1] . Transcriptional elongation is far less well understood than initiation, though proteins have been identified that influence elongation in vivo and in vitro. The general transcription factors TFIIF and TFIIH stimulate both initiation and elongation. Other factors are specific regulators of elongation, and these include the polymerase II-associated protein TFIIS, modifiers of chromatin structure and sequence-specific transactivators such as HIV Tat [2, 3] . A recent study [4] has now identified a specific regulator of elongation, dubbed Foggy, which appears to play an important role in the determination of cell fate.
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A particularly fruitful line of investigation into transcript elongation has concerned the mechanism of action of the inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB). DRB was first discovered to have anti-viral effects and was later shown to specifically inhibit elongation of polymerase II transcripts, including those activated by the HIV-1 Tat protein [5] [6] [7] [8] . DRB is an ATP analogue that inhibits a variety of protein kinases in vitro, but its in vivo target remained elusive for more than three decades. In vitro, DRB inhibits progress of polymerase II along a template early in elongation, but not after the transcript is more than 500 bases long [9] . Significant progress in understanding DRB function was made by Handa and colleagues [10, 11] , who purified two factors from HeLa nuclear extracts that are required for DRB to inhibit transcript elongation in vitro. These factors were named DRB sensitivity inducing factor (DSIF) and negative elongation factor (NELF).
Human DSIF is a heterodimer of hSpt4 and hSpt5, socalled because they are homologues of the budding yeast proteins Spt4 and Spt5. The budding yeast SPT genes were identified rather indirectly, by mutations that restored expression of a gene that had been shut off by nearby insertion of a Ty transposable element [12] . Spt5 binds to the large subunit of RNA polymerase II in vitro [10, 11, 13, 14] , and has four 'KOW' homology domains. Notably, KOW homology domains are also found in the Escherichia coli RNA polymerase-binding protein NusG, which affects transcriptional termination and anti-termination [15, 16] . NELF has five subunits, including one called RD which has a potential RNA-binding domain.
NELF and DSIF cooperatively repress elongation by polymerase II. The two proteins co-immunoprecipitate with unphosphorylated RNA polymerase IIA, but not with the polymerase II0 isoform which is hyperphosphorylated on the carboxy-terminal domain (CTD) of the large subunit. The CTD consists of repeated heptads with consensus sequence YSPTSPS. Consistent with the binding data, NELF and DSIF selectively inhibit elongation by polymerase IIA -polymerase II0 is immune to their negative effects [11] . Most polymerase II engaged on template DNA in vivo is thought to be in the phosphorylated form. Phosphorylation of RNA polymerase II is very complex, as each of the 52 heptads can potentially be phosphorylated by several different kinases at either of two different positions: serine residues 2 and 5. Whether DSIF and NELF differentially affect the various different phosphorylated forms of polymerase II remains to be determined.
Paradoxically, neither NELF nor DSIF has protein kinase activity, so they are unlikely to be direct targets of DRB. How, then, are NELF and DSIF involved in DRBmediated inhibition of elongation? The resolution of this conundrum required identification of a third factor, the 'positive transcription elongation factor b' (P-TEFb), by Price and colleagues (reviewed in [17] ). P-TEFb was isolated from Drosophila cells as an activity that stimulated elongation of polymerase II transcripts. This factor turned out to be a kinase complex composed of the cyclin-dependent kinase Cdk9 and several alternative cyclin partners -cyclin T1, T2 or K. P-TEFb hyperphosphorylates the polymerase II CTD and is inhibited by low concentrations of DRB. Both P-TEFb and Spt5 are required for HIV Tat to stimulate elongation [14, 17, 18] . Tat binds to the cyclin T subunit and drags its captive cellular kinase to viral transcription complexes, where it hyperphosphorylates the CTD to produce a supercharged polymerase for efficient elongation of vir al RNAs (reviewed in [19] ). DRB inhibits the latter step and thereby prevents Tat from activating transcription.
The connection between DRB and the negative or positive elongation factors was made by Handa and colleagues [11, 20] , who found that the only function of P-TEFb in a transcription extract was to counteract the negative effects of DSIF and NELF. When DSIF or NELF was depleted from the extract, P-TEFb was no longer required for efficient elongation. Conversely, depletion of P-TEFb inhibited elongation and mimicked the effect of adding DRB [20] (Figure 1 ). These studies show that the main mechanism controlling polymerase II transcript elongation, in vitro at least, is inhibition by DSIF and NELF, and that P-TEFb counteracts these inhibitors by phosphorylating the CTD of polymerase II and possibly also Spt5 [21] .
DSIF is more than just a simple inhibitor of elongation; rather, it appears to have a split personality. When ribonucleoside triphosphate precursors are limiting, DSIF manifests its positive qualities and actually enhances elongation [10] . A third possible function of Spt5 is in the pre-mRNA processing step that adds the 5′ cap to nascent transcripts when they are about 25 bases long. The 7-methyl G 5′ppp5′ cap stabilizes mRNA and enhances translation; Spt5 binds to, and stimulates, the guanylyltransferase that adds the cap [22] . Interestingly, capping, like transcript elongation, also requires polymerase II phosphorylation, as capping enzymes must bind to the phosphorylated CTD in order to find their substrate RNAs [23, 24] . One interesting possibility suggested by these findings is that capping enzymes, perhaps in association with Spt5, might influence polymerase II transcription.
The pioneering work on DSIF in vitro set the stage for recent investigations that have addressed questions about its role in vivo. How does this factor influence elongation on a chromatin template, which is very different from the naked DNA templates used in the in vitro studies? Is DSIF an inhibitor or an enhancer of elongation in vivo, or can it switch from one to the other? A positive role in elongation is suggested by the finding that in budding yeast the spt4 and spt5 mutants are hypersensitive to 6-azauracil, a drug that reduces the concentration of ribonucleoside triphosphates and is thought to inhibit elongation. Furthermore, conditional mutations of SPT5 were found to be suppressed by mutations in polymerase II [13] .
On the polytene chromosomes of Drosophila salivary glands, Spt5 and P-TEFb were found to co-localise at many genes [25, 26] . In chromatin immunoprecipitation experiments, before transcription was activated by heat shock, Spt5 co-localised with paused polymerase IIA at the 5′ end of heat shock genes, consistent with a negative role in elongation [26, 27] . Surprisingly, after heat shock, Spt5 was also found at the 3′ ends of activated heat shock genes, along with P-TEFb. These findings raise the question of whether Spt5 (DSIF) works in the same way at the 5′ and 3′ ends of a gene? It seems unlikely that Spt5 acting at the 3′ end of an active heat-shock gene inhibits elongation. Perhaps Spt5 inhibits elongation at 5′ end prior to heat shock, and enhances elongation after heat shock. If so, what could trigger Spt5's switch from being an inhibitor to an enhancer of elongation? One possibility is that changing the pattern of polymerase II CTD phosphorylation might be involved. In summary, the Drosophila studies show that Spt5 and P-TEFb localise to the 5′ and 3′ ends of a specific subset of transcribed genes, but they Dispatch R145
Figure 1
A model for the roles of the elongation factors P-TEFb, DSIF (Spt4-Spt5) and NELF in controlling transcription by RNA polymerase II. Top: when DSIF/NELF interact with unphosphorylated RNA polymerase II, transcriptional elongation is inhibited [10, 11] . DRB inhibits phosphorylation of the carboxy-terminal domain (CTD) of the polymerase large subunit by blocking the P-TEFb (Cdk9-cyclin T) kinase. Bottom: a gene actively transcribed by RNA polymerase II, which is mostly phosphorylated on the CTD [26] . Spt5 co-localizes with RNA polymerase II at both 5′ and 3′ ends of the gene. As polymerase travels along the gene 5′ to 3′ the state of CTD phosphorylation (Ps) changes [23, 24] . Whether DSIF (Spt4-Spt5) activates or inhibits elongation at the 5′ and 3′ ends of an actively transcribed gene is not known. A is an upstream transcriptional activator. do not unambiguously resolve whether Spt5 is working to inhibit and/or enhance elongation.
Interesting insight into the physiological importance of transcriptional regulation at the level of elongation has come from the recent description of the first metazoan SPT5 mutant [4] . The foggy mutant zebrafish was isolated in a screen for defects in expression of tyrosine hydroxylase, the enzyme that catalyses the rate-determining step in biosynthesis of the catecholamines, dopamine, noradrenaline and adrenaline. The mutant embryos have a normal gross anatomy, but die at day four of development from circulatory problems. Their primary defect is loss of catecholaminergic neurons in the peripheral and central nervous system, including the hypothalamus and retina.
The foggy gene was cloned by complementation and found to encode a 1084 residue protein with strong sequence homology to Spt5. The foggy mutation results from substitution of the evolutionarily invariant valine at position 1012 by aspartic acid.
Guo et al. [4] showed The importance of negative regulators of elongation comes as quite a surprise in light of the fact that, in vivo, chromatin is thought to be a major obstacle to polymerase movement. One might therefore have expected the primary regulators in vivo to be enhancers of elongation rather than inhibitors. Perhaps one lesson from this work is that in vivo chromatin is modified so as not to be a major limiting factor in transcript elongation.
